Cantor Fitzgerald Reiterates Overweight Rating for AxoGen (AXGN)

AxoGen (NASDAQ:AXGN)‘s stock had its “overweight” rating reissued by equities research analysts at Cantor Fitzgerald in a report released on Friday.

Other analysts also recently issued research reports about the stock. Lake Street Capital raised their price objective on shares of AxoGen from $22.00 to $26.00 and gave the stock a “buy” rating in a report on Tuesday, November 21st. Wedbush restated a “buy” rating and set a $27.00 price objective (up previously from $22.00) on shares of AxoGen in a report on Tuesday, November 21st. Roth Capital restated a “buy” rating and set a $21.00 price objective (up previously from $18.00) on shares of AxoGen in a report on Tuesday, September 12th. Jefferies Group started coverage on shares of AxoGen in a research note on Thursday, November 30th. They issued a “buy” rating and a $35.00 target price for the company. Finally, Leerink Swann lifted their target price on shares of AxoGen from $26.00 to $30.00 and gave the stock an “outperform” rating in a research note on Tuesday, November 21st. Two research analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus price target of $26.17.

Shares of AxoGen (NASDAQ AXGN) opened at $28.65 on Friday. AxoGen has a 1-year low of $8.75 and a 1-year high of $28.90. The company has a current ratio of 3.55, a quick ratio of 2.95 and a debt-to-equity ratio of 1.93. The stock has a market cap of $959.74, a PE ratio of -71.63 and a beta of 0.40.

AxoGen (NASDAQ:AXGN) last posted its quarterly earnings data on Wednesday, November 1st. The medical equipment provider reported ($0.06) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.06). AxoGen had a negative net margin of 24.74% and a negative return on equity of 91.00%. The business had revenue of $16.05 million during the quarter, compared to the consensus estimate of $15.55 million. The business’s revenue for the quarter was up 43.2% compared to the same quarter last year. analysts forecast that AxoGen will post -0.31 EPS for the current fiscal year.

In other news, Director Jamie Mark Grooms sold 84,295 shares of AxoGen stock in a transaction dated Friday, December 8th. The shares were sold at an average price of $26.38, for a total value of $2,223,702.10. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Guido J. Neels sold 1,150,000 shares of AxoGen stock in a transaction dated Monday, November 20th. The stock was sold at an average price of $19.74, for a total transaction of $22,701,000.00. The disclosure for this sale can be found here. Insiders sold 1,293,990 shares of company stock valued at $26,494,898 in the last quarter. Corporate insiders own 9.33% of the company’s stock.

Institutional investors and hedge funds have recently bought and sold shares of the company. Thompson Davis & CO. Inc. increased its stake in shares of AxoGen by 575.0% in the second quarter. Thompson Davis & CO. Inc. now owns 6,750 shares of the medical equipment provider’s stock worth $113,000 after purchasing an additional 5,750 shares in the last quarter. Neuberger Berman Group LLC purchased a new position in AxoGen during the second quarter valued at approximately $201,000. Valeo Financial Advisors LLC purchased a new position in AxoGen during the third quarter valued at approximately $244,000. Nationwide Fund Advisors grew its stake in AxoGen by 5.5% during the second quarter. Nationwide Fund Advisors now owns 14,874 shares of the medical equipment provider’s stock valued at $249,000 after acquiring an additional 774 shares in the last quarter. Finally, OxFORD Asset Management LLP purchased a new position in AxoGen during the third quarter valued at approximately $270,000. Hedge funds and other institutional investors own 66.00% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Cantor Fitzgerald Reiterates Overweight Rating for AxoGen (AXGN)” was first posted by Ticker Report and is the sole property of of Ticker Report. If you are viewing this article on another site, it was copied illegally and reposted in violation of United States & international trademark and copyright law. The correct version of this article can be read at https://www.tickerreport.com/banking-finance/3126720/axogen-axgn-now-covered-by-analysts-at-cantor-fitzgerald.html.

AxoGen Company Profile

AxoGen, Inc provides surgical solutions for peripheral nerve injuries. The company?s surgical nerve repair solutions include Avance Nerve Graft, an off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect injured peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments.

Analyst Recommendations for AxoGen (NASDAQ:AXGN)

Receive News & Ratings for AxoGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AxoGen and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

How to Trade on Forex – 8 Steps for Beginners
How to Trade on Forex – 8 Steps for Beginners
Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


Leave a Reply

© 2006-2018 Ticker Report. Google+.